{
  "id": 17730681,
  "title": "+66% since picked: Which pharma stock did our AI pick before a 30% earnings beat?",
  "url": "https://urgent.news/2026/11/02/66-since-picked-which-pharma-stock-did-our-ai-pick-before-a-30",
  "topic": "ai",
  "section": "AI",
  "published": "2026-11-02T02:39:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/66-since-picked-which-pharma-stock-did-our-ai-pick-before-a-30-earnings-beat-4989813"
  },
  "original_language": "en",
  "account": "Amneal Pharmaceuticals (NASDAQ:AMRX) was selected by an AI model as a promising mid-cap pharma stock back on June 1, 2026. Since then, the stock has seen a +66.74% increase in value. The AI recognized growth potential in Amneal, as indicated by a PEG ratio of 0.35, suggesting the market had not yet fully acknowledged the company's earnings momentum.\n\nBy mid-October 2026, Amneal had already demonstrated strong fundamentals. The company reported adjusted EPS of $0.30, surpassing analyst consensus by 30.4%. Revenue for the quarter came in at $796 million, up 10% year-over-year and 5% above forecasts. Simultaneous with these results, the FDA removed a prior safety warning on estradiol patches and approved two of Amneal's denosumab biosimilars, signaling a surge in demand for the company's products. This strategic positioning by the AI, which began on June 1, 2026 and yielded a +66.74% return before the mainstream news broke, was reinforced by these positive events. Amneal Pharmaceuticals continues to trade near its 52-week high, reflecting sustained accumulation over the past five months.",
  "summary": null,
  "key_points": [
    "Amneal Pharmaceuticals selected by AI on June 1, 2026",
    "Stock increased by +66.74% since selection",
    "FDA removed safety warning, approved denosumab biosimilars"
  ],
  "editors_take": "The AI's ability to identify undervalued growth potential before regulatory approvals and earnings beats demonstrates how machine learning can capture market momentum that traditional analyst consensus often overlooks.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}